Key words: BMI1, acute myeloid leukemia, apoptosis, stem cell self-renewal, impaired long-term expansion, whereby self-renewal capacity was lost as determined by the loss of replating capacity of the cultures. These phenotypes were also associated with increased expression levels of p14ARF and p16INK4A. Together our data indicate that BMI1 expression is required for maintenance and self-renewal of normal and leukemic stem and progenitor cells and that expression of BMI1 protects cells against oxidative stress.
Introduction
BMI1 is a member of the Polycomb group (PcG) genes, which are transcriptional repressors that play essential roles in the maintenance of appropriate gene expression during development. [1] [2] [3] [4] [5] Two distinct multiprotein PcG complexes have been identified, the Polycomb Repression Complex (PRC) 1 and PRC2. 1 The PRC2
complex is involved in initiation of silencing and contains histone deacetylases and methyltransferases that can methylate H3 lysine 9 and 27 (H3K27). 6 Deletion of PRC2 genes in mice results in embryonic lethality, emphasizing their importance in development. [7] [8] [9] PRC1 is implicated in stable maintenance of gene repression and recognizes the methylation marks set by PRC2. 10;11 Mice mutant for most PRC1 genes survive until birth as result of partial functional redundancy provided by their homologues, but developmental defects do arise thereafter as is e.g. the case in the hematopoietic compartment after deletion of BMI1. [12] [13] [14] Targeted deletion of BMI1 has shown that although the numbers of fetal liver-derived HSCs is normal in these mice, their proliferative and self-renewal capacity is severely impaired. 15;16 In adult BMI1-deficient mice, the HSCs are less frequent and display an impaired competitive repopulation capacity. 16;17 Gain-of-function studies demonstrated enhanced selfrenewal of murine HSC and with a shift in balance towards more symmetric stem cell divisions. 17 We have demonstrated that constitutive expression of BMI1 in human cord blood cells results in prolonged maintenance of the stem cell pool and enhances self-renewal of human stem and progenitor cells. 18 BMI1 is potent negative regulator of the Ink4a/Arf locus in embryonic fibroblasts. 19 This locus encodes the cell cycle
For personal use only. on . by guest www.bloodjournal.org From 4 regulators and tumor suppressor p16 and p19/p14. Increased expression of these genes was observed in the BMI1-deficient mice. 12;16;19;20 However, INK4A/ARFindependent BMI1-targets must exist as well since overexpression of BMI1 in p16/p19-deficient cells still altered HSC self-renewal phenotypes. 21 In addition to functions in normal hematopoiesis, BMI1 has been suggested to play a role in leukemogenesis as well. 15;22 In a murine model of leukemia, selfrenewal of HSCs by expression of HOXA9 and MEIS1 was severely impaired in
Bmi1
-/-cells. 15 Although functional studies have not been performed in primary human leukemic cells, we and others have shown that BMI1 expression is elevated in variety of hematological tumors, including Non-Hodgkin Lymphomas and Acute
Myeloid Leukemias (AML). [23] [24] [25] [26] In chronic myeloid leukemia (CML), BMI1
expression increases with disease progression and high levels of BMI1 correlate with reduced overall survival. 27 A small study performed on AML and myelodysplastic syndrome (MDS) patients demonstrated that high BMI1 expression correlated with poor overall survival. 28 These data suggest that (epigenetic) changes induced by BMI1
in the hematopoietic stem cell likely contribute to the development or maintenance of the leukemic phenotype and require further studies to determine whether pharmaceutical targeting of BMI1 will have beneficial effects on the treatment of patients with acute leukemia.
Here, we provide evidence that downmodulation of BMI1 using a lentiviral RNAi approach impairs self-renewal of both normal human CB CD34 + cells as well as primary AML CD34 + cells from patients. Impaired HSC self-renewal was associated with increased expression of the INK4A/ARF locus, increased apoptosis in conjunction with increased levels of ROS and reduced FOXO3A expression.
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Materials and methods

Primary cell isolation
Neonatal cord blood was obtained after informed consent from healthy full-term pregnancies from the obstetrics departments of the University Medical Center in Groningen (UMCG), Martini Hospital Groningen and Sophia Hospital in Zwolle.
Peripheral blood and bone marrow from untreated patients diagnosed with AML at the UMCG were studied after informed consent and protocol approval by the Medical Ethical Committee of the UMCG, in accordance with the Declaration of Helsinki.
After ficoll separation of mononuclear cells, CD34 + cells were enriched using a magnetically activated cell sorting (MACS) CD34 progenitor kit (Miltenyi Biotech, Nijmegen, The Netherlands).
Lentiviral virus production and infection
Lentiviral vector expressing short hairpins against human BMI1 (CS-H1-shRNA-EF-1α-EGFP) and scrambled lentiviral vectors were a kind gift from Dr. Iwama (Chiba University, Japan). 29 Lentiviral particles were produced by co-transfection of 293T cells with 0.7 μg pcDNA3-VSVg-REV, 3 μg pMDLg-RRE and 3 μg CS-H1-scrambled RNAi or CS-H1-BMI1 RNAi. The lentiviral supernatants were collected 24h later and were either used directly or stored at -80°C until further use. Cord blood CD34 + cells were cultured for 16h in HPGM supplemented with SCF (100ng/ml), Flt3 Ligand (100ng/ml; both from Amgen, Thousand Oaks, USA) and TPO (100ng/ml; Kirin, Tokyo, Japan) and subsequently transduced on retronectin (Takrara, Tokyo, Japan) coated plates in two consecutive rounds of 8 and 12 hours with lentiviral supernatant supplemented with the same cytokines and 4μg/ml polybrene.
AML CD34 + blasts were transduced as previously described. [30] [31] [32] [33] Briefly, the cells 6 were pre-stimulated for 4h in RPMI supplemented with 10% FCS, 20ng/ml IL3 (Gist-Brocades, Delft, the Netherlands), G-CSF (Rhone-Poulenc Rorer, Amstelveen, The Netherlands) and TPO and afterward transduced on retronectin coated plates in three consecutive rounds of 8 and 12h with lentiviral supernatants containing cytokines and polybrene as indicated above.
.
Ex-vivo culture of primary cells, Colony-forming Cell (CFC) and Long Term CellInitiating Cell (LTC-IC) assays
Cord blood stroma-free cultures were either propagated in serum-free HPG medium supplemented with SCF, Flt3L and TPO (all 100ng/ml) or in IMD medium supplemented with 10% FCS and IL3 (10ng/ml) and SCF (100ng/ml). For the cord blood MS-5 co-culture experiments and long-term culture-initiating (LTC-IC) assays cells were grown in α MEM (BioWhittaker) supplemented with 12.5% heatinactivated FCS, 12.5% heat-inactivated horse serum (Sigma), penicillin and streptomycin, 2 mM glutamine, 57.2 μM β -mercaptoethanol and 1 μM hydrocortisone (Sigma). AML blast cells were expanded on MS5 cells using the same co-culture medium as for the cord blood cells, but supplemented with 20ng/ml IL3, G-CSF and TPO as described previously. 23 The cultures were kept on 37°C and in 5% CO 2 .
CFC and LTC-IC assays on MS-5 stromal cells were performed as previously described. 33 Briefly, for the CFC assays, 1000 GFP Western blot analysis was performed using standard protocols. Antibody against BMI1 (Upstate, CA, USA) was used in a 1:1000 dilution and anti-GFP antibody (Santa Cruz, Heerhugowaard, The Netherlands) was used in a 1:300 dilution.
Antibody against FOXO3 (Cell Signaling) was used in 1:200 dilution and anti-actin (C4) (ICN Biomedical, Zoetermeer, The Netherlands) in 1:1000 dilution. Anti-rabbit Cy3 (Jackson ImmunoRes) secondary antibody was used in 1:1000 dilution. Slides were analyzed on Leica microscope (Leica DM RXA).
Total RNA was isolated from 1x10 5 cell using the RNeasy kit from Qiagen (Venlo, the Netherlands) and was reverse transcribed using M-MuLV reverse transcriptase (Fermentas, St Leon-Roth, Germany) according to the manufacturer's instructions.
Aliquots of cDNA were then real-time amplified using iQ SYBR Green mix (BioRad, CA, USA) on a MyIQ thermocycler (Bio-Rad) and quantified using MyIQ software (Bio-Rad). HPRT expression was used to calculate relative expression levels.
Sequences and conditions are available on request.
The fluorescence activated cell sorting analyses were performed on a FACS Calibur 
Measurement of intracellular ROS levels
Intracellular ROS levels were determined by staining with the probe for 2',7'-dichlorodihydro-fluorescein diacetate (H2DCFDA; Invitrogen, Carlsbad, CA).
H2DCFDA was added to the cell suspension of transduced cells to a final concentration of 10 μM, followed by incubation at 37°C for 20 minutes. The cell pellet was resuspended in 500 μl cold PBS and kept on kept on ice until analyzed on an LSR-II (BD, Alphen /d Rijn, The Netherlands). Where indicated, cells were treated with 100 μM NAC (A9165, Sigma).
Results
Downmodulation of BMI1 expression in cord blood CD34 + cells impairs long-term expansion and reduces progenitor and stem cell frequencies.
In order to further elucidate the role of BMI1 in human stem and progenitor cells, we Besides MS5 bone marrow stromal cocultures, stroma-independent cultures were also initiated. Similar results were obtained, whereby downmodulation of BMI1 resulted in an even more dramatic decrease in expansion in cytokine-driven liquid cultures ( Fig.2A ) and progenitor frequencies (Fig.2B) . Not only the number of CFCs was strongly reduced, also the size of colonies was reduced upon BMI1 downmodulation (Fig.2C) . No significant effects were observed on hematopoietic differentiation upon downmodulation of BMI1 (Fig.2D ).
Taken together, these data indicate that downmodulation of BMI1 in human CD34 + cells reduces their proliferative capacity and leads to impaired maintenance of stem and progenitor cells.
BMI1 downmodulation increases apoptosis and ROS accumulation.
Since both in stroma-free and co-culture experiments BMI1 knockdown resulted in impaired proliferation and reduced progenitor and stem cell frequencies, we wanted to determine whether these effects were due to increased apoptosis. To address this (Fig.4F) . cocultures. In all but one case expansion was severely impaired upon downmodulation of BMI1 ( Fig.5A and B) . In AML 6 we were not able to efficiently downregulate BMI1 expression levels (data not shown). Within these MS5 cocultures we typically observe the formation of cobblestone areas underneath the stroma within 2-5 weeks after plating and these leukemic cobblestone areas (L-CAs) contain selfrenewing properties and can be harvested and replated to give rise to new long-term expanding cultures and L-CAs. 23 As depicted in Fig.5B it has remained elusive whether the expression of BMI1 is required to maintain human stem and progenitor cells, in particular those that belong to the leukemic clone.
Downmodulation of BMI1 in AML CD34 + cells impairs their long-term expansion
In the present study utilizing efficient lentiviral loss-of-function assays, we first examined the effect of BMI1 downmodulation in cord blood CD34 + cells. Our data
show that the proliferative capacity of CD34 + cells was significantly impaired.
Specifically, progenitor and stem cell frequencies were strongly reduced as determined by CFC and LTC-IC assays, suggesting that it is particularly the immature hematopoietic compartment that is affected. The bone marrow microenvironment has been attributed with protective effects on the stem/progenitor cell compartment, and we therefore performed experiments in both bone marrow stromal cocultures as well as in more stringent cytokine-driven liquid culture conditions. We observed reduced progenitor and stem cell frequencies in both liquid cultures as well as bone marrow stromal cocultures, although the effects under liquid culture conditions were more pronounced. Thus, these data suggest that cell-intrinsic pathways are affected by BMI1 depletion, but that the presence of a protective microenvironment can A number of molecular mechanisms could underlie our observed phenotypes. In murine HSCs, overexpression of BMI1 results in enhanced symmetric cell divisions. 17 Although the mechanisms involved are not elucidated yet, it might be associated with a symmetric distribution of cell fate determinants such that the stem cell pool can be expanded. Reversely, loss of BMI1 resulted in loss of HSC self-renewal as determined in competitive repopulation assays. [15] [16] [17] Furthermore, in murine Bmi1
-/-HSCs self-renewal was impaired which was at least in part mediated via a derepression of p16-INK4A and p19-ARF. 21 We also find that p19/p14 and p16 expression is elevated in both normal as well as leukemic human CD34 + cells upon downmodulation of BMI1, suggesting a direct link between BMI1 expression and repression of this locus in human AML. Derepression of the INK4A and ARF genes might result in premature senescence, as has been shown in mouse embryonic fibroblasts, 19 and it is plausible that this might be involved in the impaired long-term expansion phenotypes that we observed in our cultures as well. However, we also observed rather immediate effects upon downmodulation of BMI1 in the hematopoietic compartment. Within a few days after transduction, strongly reduced cell counts were observed, particularly under more stringent liquid culture conditions. were observed upon depletion of BMI1. 17 These observations might reflect differences between mouse and human stem/progenitor cells, but it is perhaps more likely that the conditions under which the cells were studied might have been less stringent, as we also observe the highest apoptosis rates under more stringent conditions. Our data are in line with our previously reported gain-of-function analyses, where enforced expression of BMI1 led to a proliferative advantage and increased stem cell and progenitor frequencies of cord blood CD34 + and CD34 + 38 -cells, which was associated with reduced levels of apoptosis. 18 Also, a recent study in the NB4 cell line indicated that downmodulation of SALL4, an upstream regulator of BMI1, resulted in increased apoptosis, which could be reversed by re-introduction of BMI1. 36 Although further studies are required to reveal the underlying molecular mechanisms, it is intriguing that the BMI1 RNAi-induced apoptosis coincides with increased levels of ROS accumulation and a reduction in FOXO3A expression. In mouse studies it has been shown that upregulation of p16 and p19 leads to increased ROS production in Atm -/-mice, which resulted in a loss of the HSC pool. 37 These data suggest that HSCs and progenitors contain lower levels of ROS as compared to their mature progeny, and that these differences are critical for maintaining stem cell function. As we indeed find elevated expression levels of p16 and p14 by BMI1 knockdown, these data might suggest that derepression of p16 and p14 could account for the impaired self-renewal 39 Although in the FoxO3A-deficient mice no effects were observed on apoptosis, mice in which FOXO1, 3 and 4 were deleted a significant increase in apoptosis was noted, both in the HSC as well as myeloid progenitor compartment. 39;40 In human stem and progenitor cells, we have now coupled loss of BMI1 expression to enhanced apoptosis, possibly mediated via downregulation of FOXO3A resulting in accumulation of ROS. Thus, BMI1 might be required to protect hematopoietic stem/progenitor cells from apoptosis induced by oxidative stress conditions.
Treatment with NAC was able, at least in part, to restore progenitor frequencies in BMI1 RNAi-transduced cells. Interestingly however, progenitor frequencies were not completely restored to control levels by NAC treatment. This might be due to the fact that ROS accumulation in BMI1 RNAi-transduced cells was only partially restored by NAC treatment, or that ROS-independent pathways still play a role as well in the induction of apoptosis. Previously, we have observed that overexpression of BMI1 in human CD34 + cells results in HSC maintenance as determined by NOD-SCID engraftability, even when cells are cultured under high oxygen conditions outside of the bone marrow microenvironment. 18 Although further evidence needs to be provided, it is tempting to speculate that in human leukemias, besides facilitating symmetric stem cell divisions, the leukemic stem cell might utilize enhanced expression of BMI1 as a mode to protect itself from oxidative stress. Our observations are in line with a recent paper indicating that absence of BMI1 impairs mitochondrial function and the DNA damage response pathway. 41 Thus, since BMI1 is frequently overexpressed in human leukemias, 23;27 it will be interesting to determine whether a therapeutic window exists for the targeting of BMI1 as a treatment modality in AML.
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